Kornimate/medical-research-clean huggingface dataset:
ai-driven cognitive digital therapeutics for dementia management

Conditions: Cognitive Impairment

Summary: the study would investigate the effect of a cognitive digital therapeutics system. the intervention group would receive three digital therapeutics sessions per week for 8 weeks, while the control group would receive usual care. evaluations would be done at baseline, week 8, and week 16.


Eligibility criteria:
inclusion criteria: 1. age at least 50 years old. 2. clinical dementia rating from 0.5-1 3. physician diagnosed mild neurocognitive disorder or dementia (according to icd-11 diagnostic criteria) exclusion criteria: 1. mini-mental state examination score below 18 2. if receiving an approved alzheimer's disease treatment such as acetylcholinesterase inhibitor (acheis) or memantine or both for alzheimer's disease, must be on a stable dose for at least 4 weeks prior to baseline. 3. any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's mild neurocognitive disorder or dementia. 4. history of transient ischemic attacks (tia), stroke, or seizures within 12 months of screening. 5. any psychiatric diagnosis or symptoms (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant. 6. geriatric depression scale (gds) score greater than or equal to 10 at screening. 7. participants who were dosed in a clinical study involving any new chemical entities for ad within 6 months prior to screening unless it can be documented that the participant was in a placebo treatment arm.
perioperative insulin glargine dosing study

Conditions: Diabetes; Surgery

Summary: the main objective of this study is to compare three strategies of evening insulin glargine dosing to preoperative glucose values in patients with diabetes undergoing surgery to determine which dosing strategies most often achieves the admission target study values of 100-179 mg/dl.

there are no evidence-based guidelines for insulin glargine (lantus) dosing in the perioperative setting. insulin glargine provides peakless 24-hour coverage of basal insulin needs for people with both type 1 and type 2 diabetes. insulin glargine may be used as the sole insulin or in combination with other rapid-acting insulin to achieve glycemic control. anesthesia literature recommends that blood sugar values on insulin-dependent patients be maintained between 120-180 mg/dl in most surgeries. symptoms of low blood sugar are undetectable in anesthetized patients, and blood glucose is tested at least hourly. since patients are still awake and alert toward hypoglycemic symptoms in the preoperative area, the admission target study values are 100-179 mg/dl. glucose values greater than 200 mg/dl have been associated with increased rates of infection, and exacerbated complications if a major cardiovascular event happens. frequently insulin glargine is administered in the evening. patients who are scheduled for surgery in the morning are asked not to eat or drink after midnight. some endocrinology experts recommend that all or part of the patient's usual insulin glargine should be given to avoid high blood sugar; however, whenever insulin is given without food, the possibility of low blood sugar exists. 1. patients in group 1 will administer 80% of their usual insulin glargine dose. 2. group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose. 3. group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (fbs) range and whether the patients is also taking a rapid-acting insulin.

Eligibility criteria:
inclusion criteria: * scheduled for surgical procedure * self management of diabetes * currently on evening insulin glargine prescribed by primary care physician * age 18 or over * able to communicate clearly over the phone * pre-screened by anesthesia department \> 48 hours prior to surgery exclusion criteria: * on glucocorticoid medication * on insulin glargine dual dosing or sliding scale regimen * history of hypoglycemia unawareness * pregnancy or lactating female * on insulin glargine for \< 3 months

Keywords: diabetes insulin glargine surgery
a study of rta 402 in chronic kidney disease (ckd) patients with type 2 diabetes mellitus

Conditions: Chronic Kidney Disease; Type 2 Diabetes

Summary: a phase 2 study of rta 402 in chronic kidney disease (ckd) patients with type 2 diabetes mellitus.

to evaluate the efficacy and safety of rta 402 in patients with type 2 diabetes mellitus. to evaluate the safety and tolerability of rta 402.

Eligibility criteria:
inclusion criteria: * ckd patients with type 2 diabetes mellitus * patients whose egfr levels are eligible for this study * patients being treated with stable dose of ace inhibitors and/or arb etc. exclusion criteria: * patients with type 1 diabetes * patients with known non-diabetic renal disease * patients with a history of renal transplantation * patients with mean sbp \> 160 mmhg or mean dbp \> 90 mmhg * patients with hba1c \> 10% * patients with cardiovascular disease specified in the study protocol etc.

Keywords: ckd patients with type 2 diabetes
evaluation of hypoxia by pet with f-miso in radiation therapy of prostate cancer

Conditions: Prostate Adenocarcinoma

Summary: with functional imaging development, it becomes possible to increase radiation dose to radioresistant areas (located inside tumor volume) using radiotherapy dose-painting. this strategy is particularly suitable for prostate cancer where tumor hypoxia plays a major role in the resistance of these tumors to radiation. in order to develop intratumoral hypoxia targeting by radiotherapy dose-painting areas, we should characterize changes in hypoxia before treatment and during radiotherapy. * if hypoxia does not change during radiotherapy, radiotherapy dose-painting strategy by an "integrated" boost is performed. * if hypoxia varied (increasing or incomplete regression), a "final" boost strategy of radiotherapy dose-painting(imrt, stereotactic brachytherapy or high dose rate) after a first fractionated imrt could be considered. this study should show that pet imaging with fluoromisonidazole (18f-miso) is an available tool to physicians in assessing tumor hypoxia.


Eligibility criteria:
inclusion criteria: * histologically proven prostate adenocarcinoma * absence of metastases (lymph node or bone) * one or more tumor nodules seen on mri and pet choline. * intermediate risk : gleason 7 and psa (prostate specific antigen)\<20 ng / ml, t \<t2c or gleason 6 and psa 10-20 ng / ml, t \<t2c * no concomitant hormonal treatment. (nb: the introduction of hormone therapy during radiotherapy before the second 18f-miso is a criterion to study exit) * indication of radiotherapy up to a total dose\> 70 gy and 2 gy/day fractions * signed informed consent * social insurance exclusion criteria: * age \< 18 years old * patient protected by law

Keywords: hypoxia radiotherapy pet with 18-f-miso mri
flap preconditioning by intermittent negative pressure

Conditions: Complication of Surgical Procedure; Flap Ischemia

Summary: a randomized controlled trial to investigate the effect of negative pressure preconditioning of flaps on surgical outcome and microcirculation of the tissue.

flap surgery relies on the perfusion of the transposed or transplanted tissue. distal parts of flaps are at risk of ischemia leading to wound complications and reoperation. the potential benefit of a preconditioning protocol using foam mediated negative pressure on the flap before surgery is to be examined.

Eligibility criteria:
inclusion criteria: * all patients receiving a free or pedicled musculocutaneous m. latissimus dorsi-flap with the time frame of 5 days preconditioning. exclusion criteria: * infection of skin of planned flap.

Keywords: flap preconditioning
immunogenicity of heterologous versus homologous prime boost schedule with mrna and inactivated covid-19 vaccines

Conditions: COVID-19

Summary: this study is a randomized, simple-blinded comparative phase iii clinical trial comparing the immunogenicity of two doses coronovac to that of a first dose of coronovac (sinovac, beijing, china) followed by a booster shot with the mrna-based bnt162b2 sars-cov-2 vaccine (comirnaty, pfizer-biontech). the purpose of this study is to evaluate the superiority, safety and immunogenicity of the heterologous prime-boost coronavac/bnt162b2 vaccination to the homologous coronavac/coronavac regimen.

this study is a randomized simple-blinded comparative phase iii clinical trial in covid-19 vaccine naïve volunteers adults aged between 18 and 60 years. the purpose of this study is to evaluate the superiority, safety and immunogenicity of the heterologous prime-boost coronavac/bnt162b2 vaccination to the homologous coronavac/coronavac regimen. the study is conducted in four different sites located in the north of tunisia. a total of 240 eligible participants were included. among them, the primary end point data were available for 100 participants randomly allocated to heterologous boost group versus 99 participants randomly allocated to homologous boost dose group. participants are assigned to receive either two injections of the coronavac vaccine (1st and 2nd vaccine), or coronavac as 1st dose and pfizer as 2nd dose in 3 to 4 weeks interval. a blood sample (5ml of the whole blood) is collected for each participant at the vaccination center before the first dose injection. after verifying the absence of a sars-cov-2 infection during the interrogation (a follow-up survey), a 2nd blood sample (5ml of whole blood) is taken for each participant at the vaccination center before the second dose injection. after the two injections, a 3rd blood sample (5ml of whole blood) will be taken for each participant between day 21 and day 35 after the second dose. data collection and all samples are treated at institute pasteur of tunis.

Eligibility criteria:
inclusion criteria: * acceptance to participate in the study. * age: 18-60 years old. non-inclusion criteria: * presence of disability (mainly mental disability). * pregnancy. * patients under immunosuppressive treatment or immunocompromised individuals. * prior covid-19 infection. exclusion criteria: * occurrence of a serious adverse event (death, anaphylactic shock, ...). * subjects wishing to withdraw from the study. * occurrence of a sars-cov-2 symptomatic infection during the follow-up period.

Keywords: vaccine immunogenicity heterologous prime-boost coronavac pfizer-biontech
assessment of food intake in hospitalized patients

Conditions: Undernutrition

Summary: food provision and consumption were assessed for all hospitalized patients over a 24h-period survey. this study is a part of a control quality programme and is performed every 4 years since 1999.

during one day, a team of dieticians assessed food provided, consumed and reasons for non-consumption in all hospitalized patients receiving 3 meals/day. oral nutritional supplements, supplemental enteral and parenteral nutrition were taken into account. nutritional needs were calculated according to the espen recommendations. amount of energy and proteins provided and consumed were calculated using the nutrient analysis software winrest (fsi, noisy-le-grand, france). in 2012, the presence of healthcare-associated infections was recorded during this study.

Eligibility criteria:
inclusion criteria: * all hospitalized patients exclusion criteria: * exclusive enteral or parenteral nutrition * patients who do not receive three meals

Keywords: nutritional assessment food survey hospitalized patients hospital food
intravenous thrombolysis in acute ischemic stroke with active cancer

Conditions: Stroke; Acute Ischemic Stroke

Summary: the primary hypothesis being tested in this trial is that ischemic stroke patients with active cancer will have improved clinical outcomes when given intravenous thrombolysis compared to standard care.


Eligibility criteria:
inclusion criteria: 1. patients with clinical signs of acute ischemic stroke within 24 hours of onset or awakening with stroke (if within 24 hours from the midpoint of sleep). patients with ais within 4.5-24 hours of onset must meet the ivt inclusion criteria specified in the guideline 2. patients with active cancer (active cancer was defined as cancer diagnosed within the previous 6 months; recurrent, regionally advanced or metastatic cancer, or cancer for which treatment had been administered within 6 months, or haematological cancer without complete remission.) 3. patients ≥ 18 years old 4. informed consent has been obtained depending on local ethics requirements. exclusion criteria: (1) intended to proceed to endovascular treatment; (2) pre-stroke mrs score \> 2 (3) contraindications for ivt： 1. intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hematoma, etc.) 2. previous history of intracranial hemorrhage 3. severe head trauma or stroke history within the last 3 months 4. intracranial tumors, giant intracranial aneurysms 5. intracranial or spinal surgery within the recent 3 months 6. major surgical procedures within the last 2 weeks 7. gastrointestinal or urinary tract bleeding within the last 3 weeks 8. active visceral bleeding 9. aortic arch dissection 10. arterial puncture in a site within the last 1 week that is not easy to compress and stop bleeding 11. elevated blood pressure: systolic blood pressure ≥ 180 mmhg or diastolic blood pressure ≥ 100 mmhg 12. acute bleeding tendency, including platelet count \< 100 × 10⁹/l or other conditions 13. received low-molecular-weight heparin treatment within 24 hours 14. oral anticoagulants (warfarin) with inr \> 1.7 or pt \> 15 s; receiving heparin treatment with aptt above the upper limit of the normal range within the last 24 hours of onset, receiving thrombin inhibitors and factor xa inhibitors within the last 48 hours of onset. 15. blood sugar \ 22.22 mmol/l 16. head ct or mri indicates large-area infarction (infarction area ≥ 1/3 of the middle cerebral artery supply area) (4) the judgment is left to the discretion of the investigator
efficacy of laser acupuncture for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the laser acupuncture is a new and potential intervention for the disease of peripheral nerve. the purpose of this study was to assess the effect of laser acupucnture therapy on carpal tunnel syndrome.

laser acupuncture is combined low level laser with acupuncture points. investigators perform a prospective randomized, single-blinded study to investigate the efficacy of laser acupuncture in patients with carpal tunnel syndrome. patients were randomized into intervention and control group. participants in intervention group received six-sessions of laser acupuncture and six-sessions of sham laser acupuncture was given in control group. all participants used wrist splint at night. the evaluation was performed pretreatment as well as on the 2th, 4th, 8th and 12th week after the treatment.

Eligibility criteria:
inclusion criteria: * age between 20-80 year-old. * typical symptoms and signs of mild to moderate carpal tunnel syndrome, such as positive tinel's sign numbness/tingling in at least 5th digits, and in whom the diagnosis was confirmed using an electrophysiological study. exclusion criteria: * cancer * coagulopathy * pregnancy * inflammation status * patients who had conditions mimicking carpal tunnel syndrome, such as cervical radiculopathy, polyneuropathy, brachial plexopathy, thoracic outlet syndrome or who had previously undergone wrist surgery or steroid injection for carpal tunnel syndrome. * there are tattoos, birthmarks and skin disorders over acupuncture points.
efficacy of on-venous laser irradiation of blood on diabetes kidney disease patients

Conditions: Chronic Kidney Diseases; Proteinuria; Diabetes Mellitus

Summary: the single center, randomized, assessor- and participant-blind, controlled, cross-over on-venous laser irradiation of blood clinical trial was performed to analyze patients with dkd. the information will help to whether integration of laser acupuncture into patient care will help to improve the clinical symptoms and quality of life.

microalbuminuria is the cardinal symptom of diabetes kidney disease (dkd) and is linked to renal function decline. the cardiovascular risk of patients with dkd is much higher than that of the general population, and cardiovascular diseases is the main cause of death in patients with dkd. we plan to enroll 72 volunteer patients with microalbuminuria. after 1 week waiting period (as the waiting list group), the patients will be randomized to on-venous laser irradiation of blood and low dose olib group. each group will include 36 patients and given intervention three times a week. the intervention will then be crossed over to the other one after 1 week of wash-our period. outcome measurement includes questionnaires, biochemistry analysis, urine routine analysis.

Eligibility criteria:
inclusion criteria: 1. hba1c≥6.5 % and ≤ 9%, ±0.5% under past three months 2. egfr ≥30ml/min/1.73m2 and protinuria ≥30mg/d under acei or arb treatment exclusion criteria: 1. allergic to laser beans 2. immunosuppressive drugs had been used in the past six months 3. urine protein over 3.5 g /day 4. autosomal dominant polycystic kidney disease 5. lupus nephritis 6. people with mental illness or other mental disabilities are unable to cooperate with the researcher. 7. those who used non-steroidal analgesics and steroids in the trial period 8. pregnant or lactating women

Keywords: chronic kidney diseases diabetes mellitus
treatment of hypercholesterolaemia in hispanic subjects (starship)

Conditions: Hypercholesterolemia; Dyslipidaemia

Summary: the purpose of this study is to compare the effect of 6 weeks of treatment with rosuvastatin with 6 weeks of treatment with atorvastatin in hispanic subjects with hypercholesterolemia


Eligibility criteria:
inclusion criteria: * fasting low density lipoprotein \& triglyceride levels as defined by the protocol. * self described hispanic race * subjects with coronary heart disease or at high risk of coronary heart disease. exclusion criteria: * the use of lipid lowering drugs or dietary supplements after visit 1. * active arterial disease eg unstable angina, or recent arterial surgery * blood lipid levels above the limits defined in the protocol. * uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.

Keywords: cholesterol low density lipoproteins dyslipidaemia rosuvastatin crestor atorvastatin lipitor hispanic
social media use during covid-19

Conditions: Coronavirus; Depression; Anxiety; Stress

Summary: the investigators plan to conduct a cross-sectional survey to examine how social media use during covid-19 relates to: (1) information management, (2) assessment of the situation, and (3) affect.


Eligibility criteria:
inclusion criteria: * at least 21 years * has stayed in singapore for at least 2 years exclusion criteria: * below 21 years * has stayed in singapore for less than 2 years

Keywords: covid-19 social media communication
chest wall deformities in children - epidemiological data

Conditions: Chest Wall Deformity; Funnel Chest

Summary: pectus excavatum (pe) or funnel breast is the most common congenital deformity of the chest wall, which occurs in about 1 in 400 births with a boy to girl ratio of 4: 1 to 3: 1. the etiology of pe is largely undefined, but there are numerous indications that genetic factors play a role in the development of pe. up to 40% of patients report affected family members with similar congenital deformities. in many families, pe follows a pattern that would be compatible with an autosomal dominant or recessive pattern of inheritance. the data on the frequent occurrence of pe in family members fluctuate greatly and only a few genes associated with a pe have been identified so far.

previous studies suggest that sulfation of proteoglycans plays a crucial role in the normal development of cartilage and bone and could therefore be crucial in the genesis of the disease. the main catalytic machinery responsible for the biosynthesis and breakage of sulfate esters in the proteoglycans consists of various enzymes and transporters. mutations in sphingosine kinase 1 (sk1) and sphingosine kinase 2 (sk2) genes that encode the transmembrane transporters of sulfate or enzymes that are involved in 3'-phosphoadenosine 5'-phosphosulfate (paps) synthesis have been identified as the cause of several inherited diseases that all have skeletal system deformities. connections between chest wall deformities with syndromes (e.g. marfan, noonan), anomalies (e.g. poland, moebius) or associations (e.g. cantrell pentalogy, phace) are well known. in contrast, there have so far been hardly any genetic studies of the isolated congenital chest wall deformities. epidemiological data are insufficient and only a few groups deal with the inheritance and the incidence of this disease when it occurs in isolation.

Eligibility criteria:
inclusion criteria: * . all patients who are in the altona children's hospital or in the university hospital hamburg. funnel breast, keel breast, sternal cleft * . a signed declaration of consent from the parents or legal guardians is available * . the patient has given a declaration of consent exclusion criteria: * confirmation of another diagnosis associated with chest wall deformities: 1. marfan syndrome 2. noonan syndrome 3. poland syndrome 4. moebius syndrome 5. cantrell pentalogy 6. phace association